Table 6.
Studies on stereotactic radiotherapy for brain metastases.
| Minniti | Fahrig | Martens | Inoue | Narayana | This study | |||
|---|---|---|---|---|---|---|---|---|
| Patient No | 206 | 150 | 75 | 145 | 12 | 54 | ||
| Median size | 1.9 cc (cumulative GTV) | 6.1 cc (PTV) | 1.5 cc (GTV) | 6.9 cc (GTV) | 3.5 cm (GTV) | 1.9 cc (cumulative GTV) | ||
| Dose (Gy)/fraction | 20/1, 18/1, (15–16)/1 | 35/5 | 35/7 | 40/10 | Mainly 30/6, 35/7, 30/5 | 27/3 | 30/5 | 28/4, 28.8/4 |
| BED10 (Gy) | – | 40–49.6 | 43.8 | 56 | – | 42.8 | 40 | 47.6, 48.6 |
| LC rate at 12 months (%) | 92 | (96) | (85) | (87) | 52 | (95.8) | 70 | 91 |
| Median OS (month) | 14 | 15 | 9.1 | 7 | 8.5 | 7 | ||
| Isodose line | 87 | – | – | 60 | 100 | 80 | ||
| ≥Gr 3 acute toxicity (%) | 5.8 | 0 | 0 | 0 | – | 6.2 | Increased steroid use: 15 | 0 |
| ≥Gr 3 late toxicity (%) | 22 | 7 | 0 | 1.3 | 0 |
Abbreviations: LC, local control; OS, overall survival; Gr, grade; and BED, biologically effective dose.